EP3503870A1 - Composition de soin de la peau - Google Patents

Composition de soin de la peau

Info

Publication number
EP3503870A1
EP3503870A1 EP17754154.7A EP17754154A EP3503870A1 EP 3503870 A1 EP3503870 A1 EP 3503870A1 EP 17754154 A EP17754154 A EP 17754154A EP 3503870 A1 EP3503870 A1 EP 3503870A1
Authority
EP
European Patent Office
Prior art keywords
lactobacillus
care composition
skin care
lactic acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17754154.7A
Other languages
German (de)
English (en)
Inventor
Ursula Fritzmeier
Birgit LEWANDOWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georg Fritzmeier GmbH and Co KG
Original Assignee
Georg Fritzmeier GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg Fritzmeier GmbH and Co KG filed Critical Georg Fritzmeier GmbH and Co KG
Publication of EP3503870A1 publication Critical patent/EP3503870A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the invention relates to a skin care composition for the care of dry skin and for the relief of skin irritations.
  • the object of the invention is to achieve a skin care composition having an improved action for the care of dry skin and for the relief of skin irritations.
  • the presence of lactic acid bacteria in the normal flora of the intestine, skin and mucous membranes in humans and animals as well as their involvement in the formation and maintenance of a so-called protective shield on the skin is known.
  • the natural bacterial protective shield of the skin serves primarily to prevent the colonization of undesired microorganisms and thus to prevent a risk of infection (Georg Fuchs, Hans-Günter Schlegel, "General Microbiology", 8th Edition, Thieme Verlag (2006), p 354).
  • Lactic acid bacteria and lactic acid are therefore used in medical devices mainly to stabilize or restore them in case of disturbances or loss of the above-mentioned shield function. This is achieved by increasing and maintaining the lactic acid concentration on the skin or mucous membrane treated therewith so that the physiological pH is restored. Products relating to this are, for example, vaginal capsules or vaginal suppositories containing lactic acid bacteria and / or lactic acid.
  • EP 1995307 B1 discloses methods and means for protecting the skin from pathogenic microorganisms.
  • microorganisms of the species Lactobacillus buchneri and Lactobacillus delbgurii are used to inhibit the growth of specific pathogenic microorganisms without inhibiting the growth of Staphylococcus epidermidis attributed to the resident skin flora.
  • lactic acid bacteria used in toothpaste.
  • the active ingredient Pro-t- Action® developed by BASF and derived from lactic acid bacteria, is added to prevent the caries-producing bacterium Streptococcus mutans from adhering to the teeth.
  • lactic acid bacteria in products to be applied to the skin is limited in the prior art that it is intended to achieve or improve protection against pathogenic microorganisms.
  • the alleviation of skin irritation or a care effect on dry skin are not known.
  • a skin care composition comprising a vehicle and a proportion of lactic acid bacteria and / or their metabolites.
  • the skin care composition according to the invention has an excellent action to relieve skin irritation and is also excellent for the care of dry skin.
  • the lactic acid bacteria used in the present invention are cultured in a well known manner in a suitable nutrient solution.
  • the Lactobacillus ferment thus obtained is then used in the preparation of the skin care composition according to the invention.
  • the lactic acid bacteria may be contained in the skin care composition live or else only their metabolites.
  • the fermentation product obtained in the cultivation of the lactic acid bacteria is used either as such and thus together with the living cultures in the preparation of the skin care composition or, before use, the resulting ferment is subjected to a treatment whereby the living cultures are inactivated, ie killed.
  • thermal sterilization methods such as heat sterilization and physical sterilization methods such as radiation sterilization and sterile filtration may be cited.
  • the skin care composition according to the invention may contain both live cultures and inactive cultures of lactic acid bacteria.
  • the lactic acid bacteria are selected from one or more strains of Lactobacillus casei, Lactobacillus apis, Lactobacillus gasseri, Lactobacillus sakei, Lactobacillus lactis, Lactobacillus gastricus, Lactobacillus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus, Lactobacillus parabuchneri, Lactobacillus frumenti, Lactobacillus fermentum, Lactobacillus jensenii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus piscicola and Lactobacillus murinus.
  • the lactic acid bacteria are selected from one or more strains of Lactobacillus casei, Lactobacillus apis, Lactobacillus gasseri, Lactobacillus sakei, Lactobacillus lactis, Lactobacillus gastricus, Lactobacillus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus, Lactobacillus parabuchneri, Lactobacillus frumenti, Lactobacillus fermentum , Lactobacillus jensenii and Lactobacillus reuteri.
  • the lactic acid bacteria are particularly preferably selected from one or more strains of Lactobacillus casei, Lactobacillus apis, Lactobacillus gasseri, Lactobacillus sakei, Lactobacillus lactis, Lactobacillus gastricus, Lactobacillus fructosus, Lactobacillus plantarum, Lactococcus plantarum, Fructobacillus fructosus and Lactobacillus parabuchneri. It is most preferred that the lactic acid bacteria of the Lactobacillus plantarum strain be.
  • the lactic acid bacterial mass fraction in the skin care composition of the present invention is about at least 0.1%, preferably about 1% to 10%, and most preferably about 5%.
  • the skin care composition additionally contains chitosan or a suitable chitosan derivative such as chitosan lactate. Chitosan can also act as the carrier.
  • the skin care effect can be further improved, even if a proportion of hyaluronic acid or a suitable Hyaluronklaivats is included.
  • the vehicle is preferably a cream.
  • This cream may be based on an oil-in-water emulsion or suspension. It is also possible to use a gel matrix.
  • the skin care composition of the present invention may be formulated, for example, in the form of a cream or a gel, as set forth above.
  • Further exemplary preparation types are a serum or a bath additive.
  • a serum according to the invention is usually characterized by being liquid, having a light texture and a relatively high proportion of active ingredient.
  • An inventive bath additive is usually also liquid.
  • the skin care composition according to the invention can also be used for the production of a care dressing or a wound dressing.
  • the composition according to the invention is introduced as a nourishing additive in a suitable carrier or applied to this.
  • the carrier mixed with the skin care composition according to the invention may be applied for application to the skin area to be groomed or treated. the.
  • the materials commonly used in dressings or wound dressings can be used, such as fabrics or nonwovens made of natural or artificial fibers or plastic films.
  • the carrier may consist of a single layer or be composed of several layers, which preferably consist of different materials.
  • the skin care composition according to the invention may contain, in addition to the lactic acid bacteria or their metabolites, one or more ingredients which aid the action of the skin care composition according to the invention or which themselves have a nourishing or soothing effect.
  • chitosan and hyaluronic acid can be mentioned.
  • the skin care composition of the present invention may commonly contain adjuvants used in cosmetic articles such as solvents, humectants and moisturizing agents, emollients, emulsifiers, gellants, stabilizers, antioxidants and buffers.
  • the solvent used is preferably water.
  • the effectiveness of the skin care composition according to the invention was tested by means of a UV erythema test on the human skin of six test persons.
  • the skin of each of the test persons was irradiated with UV-B light in such a way that a visible erythema (erythema) developed.
  • the reddened areas of the skin were then treated daily with three different products A, B and C over a period of seven days, leaving a fourth part of the skin without any treatment.
  • the reddening of the skin was measured daily by means of a chromameter and additionally evaluated by the respective test persons subjectively.
  • Product A was a cream containing live cultures of Lactobacillus plantarum, chitosan and water.
  • Product B was a cream containing inactive (killed) cultures. from Lactobacillus plantarum, chitosan and water.
  • Products A and B contained the lactobacilli in a proportion of 0.3% (w / v) and chitosan in the form of chitosan lactate (molecular weight 30,000-500,000 Da) in a proportion of 10% (w / v).
  • Product C was a commercial cream containing dexpanthenol as an active ingredient (Bepanthen® from BASF) and was a comparatively well-known comparative product. The three products used in the test were neutrally packaged so that none of them did Test persons could identify which of the products contained the ingredient to be tested or was a reference sample.
  • test fields each measuring 2 cm x 2 cm were marked on the six subjects with different skin types aged 24 to 41 years on the forearm inside.
  • the irradiation with UV-B light was carried out with the device UV802L / P / UV6 (Waldmann).
  • MED minimum erythema dose - corresponds to the minimum dose to reach erythema.
  • Each of the four test fields was irradiated with the same radiation intensity.
  • Test fields A, B and C were treated with products A, B and C, respectively.
  • Field D remained untreated for the duration of the experiment.
  • the application of the preparations was started 24 hours after the UV irradiation and then took place continuously once a day. Subjects were instructed not to use any other personal care products or to take sunbaths during this time.
  • the colorimeter Chromameter CR 200 of the company Minolta was used for the quantitative determination of the color changes on the human skin.
  • a flexible measuring head (diameter 1 cm) is placed on the skin area to be examined and the color nuances of the skin are measured by emitting a flash of light (CIE standard illuminant C).
  • CIE standard illuminant C the light reflected back from the skin is measured and represented numerically in the L * a * b color system.
  • the color coordinates a * and b * where the a * coordinate is the red-green color and the b * coordinate reflects the blue-yellow coloration.
  • an increasing a * value describes a Increased redness of the skin and a decreasing a * value indicates a fading of redness.
  • three measurements were taken in succession, which were averaged and stored by the device.
  • Table 2 shows for the days 1, 2, 3, 4 and 7 the results of the skin reddenings measured by means of the chromameter, whereby for each day an average of the individual measurements of the six test persons is indicated.
  • a * value is used, as this best reflects the redness of the skin.
  • a skin care composition according to the present invention has an effect of relieving skin irritation.
  • Such a composition also has the advantage that it can be prepared in a simple manner and is also well suited for the care of dry skin.
  • a skin care composition comprising a vehicle and a proportion of lactic acid bacteria or their metabolic products.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition de soin de la peau comprenant un véhicule et une fraction de lactobacilles ou de métabolites de celles-ci.
EP17754154.7A 2016-08-24 2017-08-16 Composition de soin de la peau Withdrawn EP3503870A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102016115680 2016-08-24
DE102017103850.7A DE102017103850A1 (de) 2016-08-24 2017-02-24 Hautpflegezusammensetzung
PCT/EP2017/070778 WO2018036882A1 (fr) 2016-08-24 2017-08-16 Composition de soin de la peau

Publications (1)

Publication Number Publication Date
EP3503870A1 true EP3503870A1 (fr) 2019-07-03

Family

ID=61167399

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17754154.7A Withdrawn EP3503870A1 (fr) 2016-08-24 2017-08-16 Composition de soin de la peau

Country Status (4)

Country Link
US (1) US11357720B2 (fr)
EP (1) EP3503870A1 (fr)
DE (1) DE102017103850A1 (fr)
WO (1) WO2018036882A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4059571A4 (fr) * 2019-10-11 2023-11-15 National University Corporation Shizuoka University Bactéries d'acide lactique qui produisent du nicotinamide riboside, et bactéries d'acide lactique qui produisent du nicotinamide mononucléotide et du nicotinamide riboside
AT17326U1 (de) 2021-03-29 2021-12-15 Sanubiom Gmbh Hautpflegezusammensetzung in Pulverform, aus dem ein Gel hergestellt wird
WO2023106376A1 (fr) * 2021-12-09 2023-06-15 国立大学法人九州大学 Promoteur de production de collagène, promoteur de production d'acide hyaluronique et activateur de kératinocyte épidermique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736537A1 (fr) 2005-06-22 2006-12-27 OrganoBalance GmbH Procédés et moyens de protéger la peau contre les micro-organismes pathogènes
FR2889057B1 (fr) * 2005-08-01 2008-07-18 Oreal Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches
JP5121715B2 (ja) * 2006-08-10 2013-01-16 ハウスウェルネスフーズ株式会社 保湿剤
FR2942719B1 (fr) * 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
KR101640744B1 (ko) 2014-05-07 2016-07-19 일동제약주식회사 고분자 다당 바인더에 컨쥬게이트된 락토바실러스 람노서스 rht-3201, 및 이의 아토피 예방 및 치료 용도

Also Published As

Publication number Publication date
WO2018036882A1 (fr) 2018-03-01
DE102017103850A1 (de) 2018-03-01
US11357720B2 (en) 2022-06-14
US20190183783A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
DE69822546T2 (de) Kosmetische oder pharmazeutische Zusammensetzung, die ein Kulturmedium eines Mikroorganismus enthält
EP1269983B1 (fr) Utilisation du 1,2-décanediol contre des germes responsables d' odeurs corporelles désagréables
DE69919950T2 (de) Kosmetische zusammensetzung enthaltend einen Polysacchariden von einem hydrothermalen Bakterium
CN110585076A (zh) 一种益生元和益生菌组合物及其制备方法和应用
DE102011119033A1 (de) Verwendung von Isosorbidcaprylaten/capraten in Deodorantien und Antiperspirantien
EP3362038A1 (fr) Composition cosmétique contenant des bactéries probiotiques
EP3503870A1 (fr) Composition de soin de la peau
EP3494850B1 (fr) Lingette humide avec hydroxyacetophenon
DE69916695T2 (de) Verwendung mindestens eines Hydroxystilben als Mittel zur Verringerung der Adhäsion von Mikroorganismen
KR102160980B1 (ko) 피부 피지 조절 및 진정 효과를 갖는 화장료 조성물, 이를 이용한 화장료 및 이의 제조방법
DE102007026156B4 (de) Kosmetische Zusammensetzung mit einem Limnocitrus Littoralis-Extrakt
DE202016007098U1 (de) Creme mit Spirulina-Algen
EP2386309B1 (fr) Bulbine frutescens gel
EP1458334B1 (fr) Produit curatif et de soin a base de levain et son procede de production
DE1492023C3 (de) Hautpflegemittel
CN110711263A (zh) 一种具有防治、修复、修饰瘢痕作用的功能性敷料及其制备方法
EP2347797A2 (fr) Procédé cosmétique
KR102659310B1 (ko) 침상골편 분말을 함유하는 화장료 조성물 및 그 제조방법
DE102018106331A1 (de) Bakterien umfassende Zusammensetzung zur Geruchsreduzierung
EP2658512A2 (fr) Utilisation d'acide 13-hydroxy-9,11-octadécadiénique pour brunir la peau humaine, pour colorer les cheveux humains et pour traiter la lucite polymorphe
EP2638933A1 (fr) Produit cosmétique pour peau mâture
DE102007028028A1 (de) Sauerstoff in kosmetischen oder dermatologischen Zubereitungen
CH694753A5 (de) Medikament sowie kosmetische und dermatologische Zubereitung enthaltend ein Büffelmilchprodukt.
WO2024104650A1 (fr) Formulation de lavage anti-acné
DE102022108329A1 (de) Zusammensetzung zur Behandlung der Haut

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20190319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20191104

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603